Table 1.

Potential drugs for endothelial reprogramming therapy

Name	Brand Name	Mechanism of action	Status
Ficlatuzumab/AV-299	N/A	Monoclonal antibody against HGF	Under clinical trials
YYB101	N/A	Monoclonal antibody against HGF	Under clinical trials
Cabozantinib	Cometriq, Cabometyx	Inhibitor of c-Met (and VEGFR2, AXL, and RET)	FDA-approved for medullary thyroid cancer, kidney cancer
Olaratumab	Lartruvo	Monoclonal antibody against PDGFRα	FDA-approved for soft-tissue sarcoma (STS)
Ripretinib	Qinlock	Inhibitor of PDGFRα (and KIT)	FDA-approved for advanced gastrointestinal stromal tumor (GIST)
Sunitinib	Sutent	Inhibitor of PDGFRs (VEGFRs and KIT)	FDA-approved for renal cell carcinoma (RCC), pancreatic cancer, and imatinib-resistant gastrointestinal stromal tumor (GIST)
KPT-9274	N/A	Inhibitor of PAK4 (and NAMPT)	Under clinical trials
Panobinostat/ LBH589	Farydak	HDAC inhibitor	FDA-approved for multiple myeloma
Vorinostat/SAHA	Zolinza	HDAC inhibitor	FDA-approved for cutaneous T-cell lymphoma (CTCL)
Belinostat/ PXD101	Beleodaq	HDAC inhibitor	FDA-approved for peripheral T-cell lymphoma
Romidepsin/ FK228	Istodax	HDAC inhibitor	FDA-approved for cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs)
Azacitidine	Vidaza	DNMT inhibitor	FDA-approved for myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia
Decitabine	Dacogen	DNMT inhibitor	FDA-approved for myelodysplastic syndromes and acute myeloid leukemia (AML)
TVB-2640	N/A	FASN inhibitor	Under clinical trials
Etomoxir	N/A	CPT1A inhibitor	Under clinical trials
IACS-6274	N/A	GLS1 inhibitor	Under clinical trials